Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, has appointed Dr. Bill Marathias as vice president of Business Development for the US to assist with the company’s international growth plans.
 
Sygnature Discovery already has a growing client base in the US, and is looking to expand this further. Bill will play an instrumental part of this expansion, working with colleague Dr. Bruce Sargent, drawing on their combined experience and understanding of the US biopharmaceutical market.
 
Bill has 18 years’ experience working in scientific and business development roles at Pfizer as a Senior Principle Scientist, at Agilent Technologies as a Senior Applications Scientist in Sales and Marketing, Head of Biophysics at Beryllium Discovery Corporation and as a National Director of Business Development at ChemPartner USA.
 
Dr. Bill Marathias said, “I am proud to join Sygnature Discovery, particularly at such an exciting time in their business expansion plans. Sygnature is a highly respected research organization with a breadth of capability supported by substantial experience and truly integrated drug discovery services, which is rare in many contract research companies. By establishing a strong USA market presence and by working closely with the Sygnature team in the UK, we will provide outstanding vaule to our USA clients research efforts”.